Revision as of 03:21, 29 January 2020

Section editor
	Elizabeth J. Davis, MD Vanderbilt University Nashville, TN ejdavis25

0 regimens on this page 0 variants on this page

Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:

Guidelines

ESMO

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed

NCCN

NCCN Guidelines - Bone Cancer

Chondrosarcoma, all lines of therapy

No standard chemotherapy for grades 1 to 3 conventional chondrosarcoma
Mesenchymal chondrosarcoma has been treated with Ewing's sarcoma regimens
Dedifferentiated chondrosarcoma has been treated with osteosarcoma regimens

Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy

Malignant fibrous histiocytoma (MFH) of bone has been treated with osteosarcoma regimens

@@ Line 14: / Line 14: @@
 <big>Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the [[:Category:Bone sarcomas|category page]] for links to other sarcoma types or use one of these links:
 *[[Ewing sarcoma]]
+*[[Giant-cell tumor of bone]]
 *[[Osteosarcoma]]
 </big>
@@ Line 26: / Line 27: @@
 *Mesenchymal chondrosarcoma has been treated with [[Ewing's sarcoma|Ewing's sarcoma regimens]]
 *Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]]
-=Giant-cell tumor of bone, all lines of therapy=
-==Denosumab monotherapy {{#subobject:65e2b|Regimen=1}}==
-{| class="wikitable" style="float:right; margin-left: 5px;"
-|-
-|[[#top|back to top]]
-|}
-===Regimen {{#subobject:f50a28|Variant=1}}===
-{| class="wikitable" style="width: 50%; text-align:center;"
-!style="width: 25%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
-|-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext Thomas et. al 2010 (Amgen 20040215)]
-|style="background-color:#91cf61"|Phase II (RT)
-|-
-|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70277-8/fulltext Chawla et al. 2013 (Amgen 20062004)]
-|style="background-color:#91cf61"|Phase II (RT)
-|-
-|}
-====Chemotherapy====
-*[[Denosumab (Xgeva)]] as follows:
-**Cycle 1: 120 mg SC once per day on days 1, 8, 15
-**Cycle 2 onwards: 120 mg SC once on day 1
-====Supportive medications====
-*Calcium 500 mg PO once per day
-*Vitamin D 400 IU PO once per day
-'''28-day cycles'''
-===References===
-# '''Amgen 20040215:''' Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20149736 PubMed]
-# '''Amgen 20062004:''' Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. Epub 2013 Jul 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70277-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23867211 PubMed]
-## '''Update:''' Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. Epub 2019 Nov 6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30663-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/31704134 PubMed]
 =Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy=

Difference between revisions of "Bone sarcoma"

Revision as of 03:21, 29 January 2020

Contents

Guidelines

ESMO

NCCN

Chondrosarcoma, all lines of therapy

Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy

Navigation menu

Search